Skip to main content
. Author manuscript; available in PMC: 2021 Jan 21.
Published in final edited form as: Circulation. 2019 Nov 11;141(3):176–187. doi: 10.1161/CIRCULATIONAHA.119.043042

Table 6.

QTVI differences associated with inflammatory marker concentrations (n= 219 HIV−/ 344 HIV+) and the residual association for HIV

2nd Tertile
(vs. 1st)		 P 3rd Tertile
(vs. 1st)		 P HIV+
(vs. HIV-)
Model B 0.089
(0.022,0.157)
Model B +
CRP (μg/mL) 		0.050
(−0.021,0.122)		 0.17 0.092
(0.016,0.168)		 0.018 0.081
(0.013,0.148)
Model B +
ICAM-1 (ng/mL) 		0.014
(−0.059,0.088)		 0.70 0.075
(0.001, 0.149)		 0.049 0.079
(0.010, 0.147)
Model B +
IL-6 (pg/mL) 		0.113
(0.041, 0.186)		 0.002 0.135
(0.059, 0.211)		 <0.001 0.084
(0.016,0.151)
Model B + sCD163 (ng/mL) 0.029
(−0.045, 0.103)		 0.44 0.074
(−0.006, 0.154)		 0.070 0.081
(0.011, 0.150)
Model B +
sTNF- R2 (ng/mL) 		0.049
(−0.025, 0.122)		 0.20 0.083
(0.006, 0.161)		 0.035 0.085
(0.017, 0.153)

Each row corresponds to a separate mixed-effects model of QTVI with adjustments from Model B and the tertiles of the inflammatory marker of interest as the independent variable. Fibrinogen, MCP1, sCD14, and sTNF-R1 were also modeled but had P-values >0.10 and are not reported.